Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fuji Pharma Co., Ltd. (4554.T)
JPY1,966.00
+27.00 (+1.39%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address
5-7 Sanban-cho 102-0075
Tokyo, JP
Tokyo, JP
CEO
Shuhei Morita
Website
fujipharma.jp
IPO
2010-02-22
ISIN JP3816200004
Description
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,966.00
+27.00 (+1.39%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
127.2K
Beta
0.33
Float Shares
12.28M
Free Float %
50.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.59% | -10.93% | -18.83% | -10.53% | +21.34% | +5.50% | +58.13% | +73.09% | +77.51% | +100.60% | +144.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,966.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.29
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.0% ★ Q1'26: +24.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-51.4% Q1'26: +27.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.7% Q1'26: +27.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.7% Q1'26: +11.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.3% Q1'26: +7.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.4% Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.45× Q1'26: 2.78× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 2 Rev. Ana. 2 EPS Ana. |
Sep 2027 2 Rev. Ana. 2 EPS Ana. |
Sep 2028 2 Rev. Ana. 2 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31.68B
est: 31.85B (-0.5%)
|
34.23B
est: 34.70B (-1.4%)
|
35.39B
est: 36.55B (-3.2%)
|
37.91B
est: 38.20B (-0.8%)
|
36.28B
est: 36.80B (-1.4%)
|
33.79B
est: 33.60B (+0.6%)
|
33.99B
est: 34.40B (-1.2%)
|
35.43B
est: 35.50B (-0.2%)
|
40.89B
est: 43.05B (-5.0%)
|
46.14B
est: 45.26B (+1.9%)
|
51.68B
est: 49.70B (+4.0%)
|
55.43B
49.86B – 61.00B
+11.5% YoY
|
60.56B
53.11B – 68.00B
+9.3% YoY
|
74.00B
65.70B – 82.30B
+22.2% YoY
|
60.01B
53.28B – 66.75B
-18.9% YoY
|
| EBITDA |
5.33B
est: 6.08B (-12.4%)
|
5.49B
est: 6.63B (-17.2%)
|
6.34B
est: 6.98B (-9.2%)
|
6.64B
est: 7.30B (-9.0%)
|
6.30B
est: 7.03B (-10.3%)
|
5.20B
est: 6.42B (-19.0%)
|
5.46B
est: 6.57B (-17.0%)
|
6.52B
est: 6.78B (-3.8%)
|
6.88B
est: 7.32B (-6.0%)
|
7.56B
est: 7.70B (-1.8%)
|
8.96B
est: 8.45B (+6.0%)
|
9.42B
8.48B – 10.37B
+11.5% YoY
|
10.30B
9.03B – 11.56B
+9.3% YoY
|
12.58B
11.17B – 13.99B
+22.2% YoY
|
10.20B
9.06B – 11.35B
-18.9% YoY
|
| EBIT |
3.25B
est: 3.73B (-12.8%)
|
3.57B
est: 4.06B (-12.1%)
|
4.32B
est: 4.28B (+0.8%)
|
4.39B
est: 4.47B (-1.8%)
|
4.17B
est: 4.31B (-3.1%)
|
3.14B
est: 3.93B (-20.2%)
|
3.35B
est: 4.03B (-16.8%)
|
3.78B
est: 4.16B (-9.1%)
|
3.86B
est: 4.13B (-6.7%)
|
3.88B
est: 4.35B (-10.7%)
|
4.99B
est: 4.77B (+4.5%)
|
5.32B
4.79B – 5.86B
+11.5% YoY
|
5.82B
5.10B – 6.53B
+9.3% YoY
|
7.11B
6.31B – 7.90B
+22.2% YoY
|
5.76B
5.12B – 6.41B
-18.9% YoY
|
| Net Income |
2.09B
est: 1.76B (+19.1%)
|
2.12B
est: 1.98B (+7.1%)
|
3.30B
est: 2.55B (+29.6%)
|
3.37B
est: 2.77B (+21.6%)
|
2.96B
est: 2.70B (+9.6%)
|
2.09B
est: 1.37B (+52.0%)
|
2.43B
est: 2.01B (+21.1%)
|
2.70B
est: 2.71B (-0.5%)
|
3.44B
est: 5.92B (-42.0%)
|
6.15B
est: 5.31B (+15.8%)
|
3.00B
est: 3.48B (-13.9%)
|
3.21B
2.99B – 3.44B
-7.8% YoY
|
4.68B
3.47B – 5.88B
+45.5% YoY
|
5.24B
4.87B – 8.39B
+12.1% YoY
|
4.23B
3.61B – 4.85B
-19.3% YoY
|
| SGA |
7.23B
est: 5.50B (+31.5%)
|
7.42B
est: 5.99B (+23.8%)
|
7.86B
est: 6.31B (+24.6%)
|
9.05B
est: 6.59B (+37.3%)
|
8.96B
est: 6.35B (+41.0%)
|
8.05B
est: 5.80B (+38.8%)
|
8.34B
est: 5.94B (+40.5%)
|
7.36B
est: 6.13B (+20.0%)
|
8.33B
est: 9.20B (-9.5%)
|
9.23B
est: 9.68B (-4.6%)
|
10.96B
est: 10.62B (+3.1%)
|
11.85B
10.66B – 13.04B
+11.5% YoY
|
12.94B
11.35B – 14.54B
+9.3% YoY
|
15.82B
14.04B – 17.59B
+22.2% YoY
|
12.83B
11.39B – 14.27B
-18.9% YoY
|
| EPS |
68.77
est: 72.00 (-4.5%)
|
70.80
est: 81.07 (-12.7%)
|
110.30
est: 104.40 (+5.7%)
|
112.67
est: 113.60 (-0.8%)
|
97.02
est: 110.70 (-12.4%)
|
66.92
est: 56.20 (+19.1%)
|
90.52
est: 82.30 (+10.0%)
|
110.98
est: 111.10 (-0.1%)
|
141.35
est: 243.56 (-42.0%)
|
252.81
est: 217.60 (+16.2%)
|
122.93
est: 142.80 (-13.9%)
|
131.80
122.60 – 141.00
-7.7% YoY
|
191.60
142.10 – 241.10
+45.4% YoY
|
271.80
199.67 – 343.93
+41.9% YoY
|
173.30
148.02 – 198.58
-36.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
6.80B
OE per share TTM
278.39
Owner's Yield
11.66%
Maintenance CapEx ratio
105.16%
Maint CapEx / Avg PPE
43.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 34 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.05% | 188.5K | 0.58% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.03% | 1.40M | 0.42% |
| 3 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.02% | 72.7K | 0.31% |
| 4 | Avantis International Small Cap Value ETF AVDV | 0.01% | 2.46M | 0.36% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 82.2K | 0.40% |
| 6 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.01% | 99.0K | 0.39% |
| 7 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 27.1K | 0.30% |
| 8 | Amundi Japan TOPIX II UCITS ETF EUR Hedged Dist JPNH.PA | 0.01% | 49.4K | 0.45% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 361.3K | 0.06% |
| 10 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.01% | 48.6K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.01M
Shares Outstanding
24.46M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsuya Mitsuhashi | Managing Executive Officer & Corporate Planning Department | — | male |
| Hitoshi Yokoyama | Executive Officer & Head of Pharmaceutical Business Division | — | — |
| Masayuki Naganawa | Managing Executive Officer & Head of Research and Development | — | — |
| Satoshi Suzuki | Executive Vice President, Head of Business Strategy Division & Director | — | male |
| Shuhei Morita | President, Chief Executive Officer & Director | — | male |
| Toyoyuki Kamide | Executive VP, Head of Corporate Management & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4554.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
